Search

Your search keyword '"Ding, Y.C."' showing total 191 results

Search Constraints

Start Over You searched for: Author "Ding, Y.C." Remove constraint Author: "Ding, Y.C."
191 results on '"Ding, Y.C."'

Search Results

3. Polygenic risk modeling for prediction of epithelial ovarian cancer risk

6. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

7. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

8. Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers (Nature Communications, (2021), 12, 1, (1078), 10.1038/s41467-020-20496-3).

9. Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction (Nature Genetics, (2021), 53, 1, (65-75), 10.1038/s41588-020-00748-0).

10. Erratum: Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers (Nature communications (2021) 12 1 (1078)).

11. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants.

12. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers.

13. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction.

14. Characterization of the Cancer Spectrum in Men with Germline BRCA1 and BRCA2 Pathogenic Variants: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).

17. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes

18. Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness

19. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants

20. Association of genomic domains in BRCA1 and BRCA2 with prostate cancer risk and aggressiveness.

21. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes.

24. The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer.

25. Correction to: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci (Nature Genetics, (2018), 50, 7, (928-936), 10.1038/s41588-018-0142-8).

26. Germline variation at 8q24 and prostate cancer risk in men of European ancestry.

27. Erratum to: Germline variation at 8q24 and prostate cancer risk in men of European ancestry (Nature Communications, (2018), 9, 1, (4616), 10.1038/s41467-018-06863-1).

28. Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci (Nature Genetics, (2018), 50, 7, (928-936), 10.1038/s41588-018-0142-8).

29. Deposition of resistant bacteria and resistome through FMT in germ‐free piglets.

31. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations

32. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.

33. Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants.

35. Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores

36. Evaluation of polygenic risk scores for breast and ovarian cancer risk prediction in BRCA1 and BRCA2 mutation carriers

37. Actuator Saturation and Control Design for Buildings Structural Systems with Improved Uncertainty Description

38. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer

39. Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3

40. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer

41. BRCA2 polymorphic stop codon K3326X and the risk of breast, prostate, and ovarian cancers

42. A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers

43. BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers

44. Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3

45. Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer

47. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer

48. Identification of six new susceptibility loci for invasive epithelial ovarian cancer

49. Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers

50. An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers.

Catalog

Books, media, physical & digital resources